Featured Stock to Focus: Accuray Inc. (NASDAQ:ARAY)

96

Accuray Incorporated (NASDAQ:ARAY) belonging to the Medical sector which declined -6.12% and closed its last trading session at $5.98.

The company reported its last EPS on 6/30/2016 and is expected to report its next EPS on 11/3/2016. Currently, the stock has a 1 Year Price Target of $8.5.

The consensus recommendation, according to Zacks Investment research, is 1. The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell. The Stock had a 1.5 Consensus Analyst Recommendation 30 Days Ago, whereas 60 days ago and 90 days ago the analyst recommendations were 1.5 and 1.5 respectively.

Accuray Incorporated on 6/30/2016 reported its EPS as $-0.09 with the analysts projecting the EPS of the stock as $-0.07. The company beat the analyst EPS Estimate with the difference of $-0.02. This shows a surprise factor of -28.6%.

Many analysts have provided their estimated foresights on Accuray Incorporated Earnings, with 8 analysts believing the company would generate an Average Estimate of $-0.1. Whereas they predicted High and Low Earnings Estimate as $-0.03 and $-0.13 respectively. While in the same Quarter Previous year, the Actual EPS was $-0.12.

Analysts are also projecting an Average Revenue Estimate for Accuray Incorporated as $89.49 Million in the Current Quarter. This estimate is provided by 7 analysts. The High Revenue estimate is predicted as 91.6 Million, while the Low Revenue Estimate prediction stands at 86.6 Million. The company’s last year sales total was 89.63 Million.

For the Current Quarter, the growth estimate for Accuray Incorporated is 16.7%, while for the Next Quarter the stock growth estimate is 37.5%. In the past 5 years, the stock showed growth of -25.46% per annum. While for the next 5 years, the growth estimate is -259.1%.

The Company got Initiated by RBC Capital Mkts on 22-Dec-15 to Sector Perform.

Insider Trades for Accuray Incorporated show that the latest trade was made on 28 Aug 2016 where Nouri Alaleh, the General Counsel completed a transaction type “Sell” in which 976 shares were traded at a price of $5.39.

 

7 analysts projected Price Targets for Accuray Incorporated. The analysts believe that the company stock price could grow as high as $12. The Low Price target projection by analysts is $5.5 and the Mean Price Target is $8.5.

Accuray Incorporated (NASDAQ:ARAY) has the market capitalization of $477.08 Million. The company rocked its 52-Week High of $7.54 on Nov 11, 2015 and touched its 52-Week Low of $4.75 on Jul 7, 2016. The stock has Return on Assets (ROA) of 0 percent. Return on Equity (ROE) stands at 0% and Return on Investment (ROI) of -2.7 percent.

The stock is currently showing YTD performance of -11.41 Percent. The company has Beta Value of 1.33 and ATR value of 0.22. The Weekly and Monthly Volatility stands at 5.12% and 3.52%.

Company profile:

ACCURAY INCORPORATED based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 40,000 patients worldwide and currently more than 130 systems have been installed in leading hospitals in the Americas, Europe and Asia.